| Literature DB >> 12375882 |
A McCluskey1, S P Ackland, E Gardiner, C C Walkom, J A Sakoff.
Abstract
Recent investigations in our laboratories have highlighted that the inhibition of the serine/threonine protein phosphatases 1 and 2A (PP1 and PP2A) is an excellent target for the development of novel anti-cancer agents. Using a combination of the known crystal structure of PP1 and the modelled structure of PP2A, we have rationally designed a new class of protein phosphatase inhibitors, cantharimides, which exhibit broad-spectrum anti-cancer activity. Synthetic modifications of the simplest known PP1 and PP2A inhibitor, norcantharidin, has led to the development of potent PP1 and PP2A inhibitors.Entities:
Mesh：
Substances：
Year: 2001 PMID： 12375882
Source DB: PubMed Journal: Anticancer Drug Des ISSN： 0266-9536